Technological offer

Nanoparticles comprising an iron oxide core doped with radioisotope 223Ra and a coating layer of an organic compound, which may have application as radiotheranostic agents and in the treatment of cancer.

Compounds useful as reversible light-regulated agonists for activation of Vitamin D receptor (VDR) using wavelengths suitable for phototherapy, that would avoid the appearance of secondary effects, with application for the treatment of diseases that involve an alteration of the VDR function.

Design of a novel proteolytic set of chimeras (26STACs) directed at the degradation of the ceramide transfer protein CERT-1 by the proteasome, in an E3-independent manner, for its use in the treatment of breast cancer.

Novel antiviral strategy targeting viral non-essential proteins (NEPs), scarcely prone to adaptive mutations. As a proof of concept, SARS-CoV-2 ORF9b homodimerization inhibitors have been identified that prevents the virus hyperinflammation response.

Andrographolide derivatives for its use as treatment for inflammatory diseases related to cytokine storm.

New family of molecules with potent and selective antiviral activity in cellular models of infection by various coronaviruses such as SARS-CoV-2, MERS-CoV, hCoV-229E. They do not show cytotoxicity or activity against other viruses with RNA genome such as West Nile fever virus, dengue virus and vesicular stomatitis virus at relevant doses.

Novel small molecules as valuable agents for controlling bleeding after heparin treatment. Lead compound studied has shown high efficacy and is expected to overcome side effects produced by current antidotes used in clinics.